# Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01301833` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01301833](<https://clinicaltrials.gov/study/NCT01301833>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01301833

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 462 participants.

## Technical summary

Registry record NCT01301833. Non-randomized; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2015-08-28.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 462 participants (enrolled count; ClinicalTrials.gov record NCT01301833, source copy `cardio:ctgov-nct01301833-2026-01-02`, retrieved 2026-10-26)
- Start date: 2011-02 (registry gives no type) (ClinicalTrials.gov record NCT01301833, source copy `cardio:ctgov-nct01301833-2026-01-02`, retrieved 2026-10-26)
- Primary completion: 2012-09 (actual) (ClinicalTrials.gov record NCT01301833, source copy `cardio:ctgov-nct01301833-2026-01-02`, retrieved 2026-10-26)
- Completion: 2012-09 (actual) (ClinicalTrials.gov record NCT01301833, source copy `cardio:ctgov-nct01301833-2026-01-02`, retrieved 2026-10-26)
- Results first posted: 2015-08-28 (ClinicalTrials.gov record NCT01301833, source copy `cardio:ctgov-nct01301833-2026-01-02`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01301833, source copy `cardio:ctgov-nct01301833-2026-01-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01301833-2026-01-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): teneligliptin
- Intervention (Drug): glinide
- Intervention (Drug): biguanide
- Intervention (Drug): alpha-glucosidase inhibitor
- Lead sponsor: Tanabe Pharma Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Tanabe Pharma Corporation (`cardio:org-tanabe-pharma-corporation`)

## Provenance

Content hash: 0d739827f35b16d2b34f49b3ca22b24b359c9a85864201b3d4f5a2b80630bb51
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
